ReviewFrontiers in pharmacology2026
Signaling network inhibition by selected traditional Chinese medicine preparations: a novel multi-target paradigm for colorectal cancer therapy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a significant global health burden, with drug resistance, recurrence, and metastasis posing major therapeutic challenges. Traditional Chinese Medicine (TCM), employing a holistic "multi-component, multi-target, multi-pathway" strategy, offers a promising complementary approach. This review systematically summarizes recent advances in how TCM monomers and formulations regulate key CRC signaling pathways-including PI3K/Akt/mTOR, MAPK, Wnt/β-catenin, Hedgehog, and NF-κB-to inhibit tumor proliferation, promote apoptosis, suppress metastasis, and remodel the tumor microenvironment. Emphasis is placed on TCM's unique modulation of pathway crosstalk, providing new insights into its ability to reverse drug resistance and enhance chemosensitivity. The review further proposes and discusses the future translational potential of TCM-based "signaling network inhibitors" as an innovative strategy in CRC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.